Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Summit Technology (BEAM) -- Ignore unavailable to you. Want to Upgrade?

To: pappy who wrote (767)	3/17/1998 4:22:00 AM
From: majormember	Respond to of 1386

Don't think that's about to happen. SNRS has no intention of merging; it's mgmt. much more savvy than BEAM or VISX, president ex. Sr.V.P. Allergan 180 MIL optometrics devices. Total combined Sr. level experience over 100+ years. Red Chip says mgmt. MUCH BETTER than VISX/BEAM. BEAM was stupid enough to open it's own retail outlets, incurring wrath of Dr's. BEAMS excimer inferior to VISX. SNRS market model with hyperopics superior to VISX/BEAM. Cost of LTK 200K with $100 per eye vs. $500K and 50K mainteniance for excimer. SNRS is NOT in competition, but at it's current price level has MUCH more upside potential. SNRS is just beginning it's upward price cycle. BEAM won't get any more royalties from VISX and with inferior excimer, isn't going anywhere, IMHO. Regards, Skane